Bavituximab Presentation Details:
Preliminary data from a Phase II clinical trial evaluating bavituximab in combination with docetaxel in advanced breast cancer patients will be the subject of an oral presentation at 10:30 AM EDT on June 1, 2009. A second presentation detailing preliminary results from a Phase I clinical trial evaluating bavituximab as solo therapy in patients with advanced refractory cancer will be discussed in a poster session from 1:00 PM to 5:00 PM EDT, also on June 1, 2009.
Title: Phase II study of bavituximab plus docetaxel in patients with locally advanced or metastatic breast cancer.
Authors: D. Tabagari, G. Nemsadze, M. Jincharadze, M. Janjalia, J. Shan
Time: Monday June 1, 10:30 AM
Location: Level 4, Valencia Room, W415A
Abstract No: 3005
Title: Phase I study of bavituximab, a novel anti-phosphatidylserine monoclonal antibody in patients with advanced refractory cancer: Preliminary results.
Authors: N. K. Ibrahim, L. Wong, L. Rosen, J. Shan
Time: Monday June 1, 1:00 PM to 5:00 PM
Location: Level 2, West Hall C
Abstract No: 1080
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information ab
|SOURCE Peregrine Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved